Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

61.71 +0.44 (+0.72%)
Streaming Delayed Price Updated: 11:45 AM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 331,648
Open 61.55
Bid (Size) 61.69 (2)
Ask (Size) 61.73 (1)
Prev. Close 61.27
Today's Range 60.89 - 62.59
52wk Range 50.27 - 70.36
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
Via Benzinga
Topics Death
Exposures Death
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi... 
Via Benzinga

Performance

YTD
-5.71%
-5.71%
1 Month
+6.09%
+6.09%
3 Month
+13.50%
+13.50%
6 Month
+3.49%
+3.49%
1 Year
-4.93%
-4.93%

More News

Read More
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Analyst Ratings For Incyte
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
Via Chartmill
NASDAQ:INCY is not too expensive for the growth it is showing.
Via Chartmill
Analyst Expectations For Incyte's Future
Via Benzinga
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via Chartmill
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Stocks Chop As Wall Street Unpacks Powell Comments
Via Talk Markets
Topics Economy
Exposures Interest Rates
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
Via Chartmill
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
Via Benzinga
Topics Stocks
Exposures US Equities
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.